{"id":29376,"date":"2023-01-18T15:40:38","date_gmt":"2023-01-18T10:10:38","guid":{"rendered":"http:\/\/finservwealth.com\/eris-lifesciences-falls-as-margins-contract-derma-brands39-acquisition-fails-to-cheer-street\/"},"modified":"2023-01-18T15:40:38","modified_gmt":"2023-01-18T10:10:38","slug":"eris-lifesciences-falls-as-margins-contract-derma-brands39-acquisition-fails-to-cheer-street","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/eris-lifesciences-falls-as-margins-contract-derma-brands39-acquisition-fails-to-cheer-street\/","title":{"rendered":"Eris Lifesciences falls as margins contract; derma brands#39; acquisition fails to cheer Street"},"content":{"rendered":"<p> Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal.<\/p><div id=\"finse-3070006550\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/eris-lifesciences-falls-as-margins-contract-derma-brands39-acquisition-fails-to-cheer-street_16810401.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal. Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/eris-lifesciences-falls-as-margins-contract-derma-brands39-acquisition-fails-to-cheer-street_16810401.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/eris-lifesciences-falls-as-margins-contract-derma-brands39-acquisition-fails-to-cheer-street_16810401.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal. Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/eris-lifesciences-falls-as-margins-contract-derma-brands39-acquisition-fails-to-cheer-street_16810401.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Eris Lifesciences announced acquisition of nine dermatology brands from Glenmark Pharma for Rs 340 crore. The brands include Onabet, Halobate, Sorvate, and Demelan for India and Nepal.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-29376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2022\/200x200\/p\/pharma_tablet_capsule_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/29376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=29376"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/29376\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=29376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=29376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=29376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}